3/3. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/nrNF7FmY6I
RT @DrNecmettinUnal: Bu gün Lancette iki ayrı #covid19 aşısı ile alakalı makale yayınlandı. İlki Oxford'dan Faz1/2, ikincisi Çinden Faz2 ar…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @Vic_Gill: 7 months ago, scientists in China published the genetic code for SARS-CoV-2. The speed of this achievement blows my mind. Sc…
RT @MonsieurQFB: Por la mañana tuvimos la publicación de los resultados de Fase I/II de la vacuna de Oxford - AstraZeneca ( https://t.co/dE…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @AB_Algaissi: أخبار جميلة اليوم عن اللقاحات: نشر نتائج المرحلة السريرية ١ للقاح جامعة أكسفورد والنتائج مشجعة جداً. https://t.co/qzBJVYI…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
Here We Are....Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/Q6VamkQ8xV
7-20-2020: Here's the complete information from Lancet for the CanSino and the Oxford/AstraZeneca COVID-19 vaccines, which might protect humans adequately for just the first 2 months: https://t.co/mdSqJ37Swt https://t.co/LOvAzgmjrN https://t.co/UMuHvwDaLS
RT @AlvarezMorenoC: 2) La vacuna #COVID19 vectorizada en adenovirus-5 mostró en un estudio fase 2 en 603 voluntarios, seguridad aceptable…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @SIDPharm: Check out the phase 1/2 vaccine trials published in @TheLancet today #COVID19 #IDTwitter ChAdOx1 https://t.co/HhLxI684bs Ad…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @AndyBiotech: #COVID19 The most interesting data point in Cansino Ph2 is that we see data for the 1st time for the most vulnerable older…
Insisto,hay laboratorios (2), que ya han superado las fases I/II, pero aun falta la fase III de investigación. Por lo tanto aún faltan varios meses para decir que tenemos vacuna . Sigan uds todas las medidas de prevención o no tendrán uds la oportunidad
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @LLopezGonzalez: 4/4 Another experimental #COVID19 vaccine in China also released promising early results when researchers tested to see…
RT @TheLancet: Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection https:/…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/aZgbPZZbbn
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
Háblame @OJMata_ la vacuna como que si llega este año
RT @BiotechMania: 中国カンシノ社が開発中のアデノウイルスベクターのCOVID-19ワクチンの第2相試験結果がLancetに掲載。 死亡率が高く最も重要な対象年齢である55歳以上で明らかに免疫反応が劣り、中和抗体陽性抗体価・陽性率が低いことは要注意だろう。 ht…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @MinatoNakazawa: 原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなるか
RT @VivekSubbiah: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or…
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial https://t.co/aDs6C1MKav
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @mayogastro: Excelente. Esta vacuna parece efectiva con pocos efectos 2rios. Immunogenicity and safety of a recombinant adenovirus type-…
RT @infecto79: Resultados muy prometedores de la vacuna con base en vectores "Ad5-vectored COVID-19 vaccine" a dosis de 5 × 10¹⁰ ...en ma…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @LuisZuritaG: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or…
RT @EricTopol: And another adenovirus vector vaccine Phase 2 trial (CanSIno) in China, published @TheLancet today, also found neutralizing…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @TheLancet: The primary objective of the study was to evaluate the immune response and safety of the vaccine, and to determine the most…
RT @TheLancet: Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection https:/…
RT @MinatoNakazawa: 原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなる…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @mfespinosaEC: Llenan de esperanza resultados de vacuna contra #COVID19 de @UniofOxford. De ser positivos, no olviden que la humanidad p…
RT @infecto79: Resultados muy prometedores de la vacuna con base en vectores "Ad5-vectored COVID-19 vaccine" a dosis de 5 × 10¹⁰ ...en ma…
RT @TheTrueTankMan: This is big.
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @TheLancet: Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection https:/…
RT @BiotechMania: 中国カンシノ社が開発中のアデノウイルスベクターのCOVID-19ワクチンの第2相試験結果がLancetに掲載。 死亡率が高く最も重要な対象年齢である55歳以上で明らかに免疫反応が劣り、中和抗体陽性抗体価・陽性率が低いことは要注意だろう。 ht…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @TheLancet: The primary objective of the study was to evaluate the immune response and safety of the vaccine, and to determine the most…
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @MaribelRCoronel: China no se quiere quedar atrás con su #vacuna contra #COVIDー19 / @TheLancet reporta q estando en fase 2, es segura y…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @mfespinosaEC: Llenan de esperanza resultados de vacuna contra #COVID19 de @UniofOxford. De ser positivos, no olviden que la humanidad p…
RT @biofaba: Los cientificos chinos han publicado tb un artículo hoy sobre su test de vacuna. Fase 2,respuesta humoral y celular, doble bli…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @MonsieurQFB: Por la mañana tuvimos la publicación de los resultados de Fase I/II de la vacuna de Oxford - AstraZeneca ( https://t.co/dE…
RT @MinatoNakazawa: 原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなる…
RT @AndyBiotech: #COVID19 The most interesting data point in Cansino Ph2 is that we see data for the 1st time for the most vulnerable older…
RT @infecto79: Resultados muy prometedores de la vacuna con base en vectores "Ad5-vectored COVID-19 vaccine" a dosis de 5 × 10¹⁰ ...en ma…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @mfespinosaEC: Llenan de esperanza resultados de vacuna contra #COVID19 de @UniofOxford. De ser positivos, no olviden que la humanidad p…
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet https://t.co/or8C3A3I8B
RT @UnrollHelper: @sayanbastian Hi, the unroll you asked for: @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and indu…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @MinatoNakazawa: 原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなる…
RT @MinatoNakazawa: 原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなる…
RT @MinatoNakazawa: 原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなるか
Por la mañana tuvimos la publicación de los resultados de Fase I/II de la vacuna de Oxford - AstraZeneca ( https://t.co/dEpDEdh3q6 ) y los resultados de fase II de la vacuna de CanSino ( https://t.co/mmmnC5jvII ) Ambas con Resultados prometedores. https
Llenan de esperanza resultados de vacuna contra #COVID19 de @UniofOxford. De ser positivos, no olviden que la humanidad pide su acceso universal! Comparto informe preliminar sobre el tema de @TheLancet. Tengo el honor de pertenecer a su Comisión #COVID19.
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
原著論文は https://t.co/mudsNZi4Uf だが,Lancetの同じ号には,中国発のワクチン候補の第2相臨床試験も安全で有効だったとする原著論文も載っている https://t.co/3iQbFRTGBG 第3相でどうなるか
Very hopeful with encouraging results on the #COVID19 vaccine by @UniofOxford. If positive, humanity calls for its universal access! See a preliminary report on the subject on @TheLancet. I am honored of being a member of its Commission #COVID19 https://t.
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @pokrath: Ref 1. mRNA vaccine https://t.co/hjEPxcG3sz 2. Oxford vaccine https://t.co/oDJwiMGYwl 3. Cansino vaccine (จีน) https://t.co/Tb…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @infecto79: Resultados muy prometedores de la vacuna con base en vectores "Ad5-vectored COVID-19 vaccine" a dosis de 5 × 10¹⁰ ...en ma…
RT @DrMHFriedlander: This is very exciting progress in the #COVID19 vaccine development. https://t.co/C280Dgr9A0
RT @FabBallarini: BUENAS NOTICIAS Se acaban de publicar 2 papers contando los avances sobre 2 vacunas. En ambos casos se muestra respuest…
RT @TheLancet: Just added to The Lancet's #COVID19 Resource Centre—Safety and immunogenicity of two COVID-19 vaccine trials: ChAdOx1 https:…
RT @eileeniorio: @garethicke Chinese vaccine only phase 2 also. No idea if they work beyond 28 days in healthy people. Severe side effect…
RT @pmarsupia: 🔴 Más buenas noticias! The Lancet también ha publicado los resultados de la Fase II de la farmacéutica china CanSino (sí,…
RT @TheLancet: NEW—Chinese phase 2 trial finds #COVID19 vaccine is safe and induces an immune response https://t.co/y19Tg7VmUT https://t.co…